Nanobiotix is no longer the company that has to fund its own registrational trial. Johnson and Johnson now sponsors the global head and neck study, and the United States regulator has accepted the partner's protocol rewrite that drops the interim look and pulls the final analysis forward on fewer events. That change, paired with a completed follow-on in May, is what the market is actually trading. The equity is a claim on a partnered physics-based radioenhancer, not a self-funded development story. Laurent Levy's group still owns the science and a royalty strip. The partner owns the clock, the sites, and almost all of the remaining trial spend. Shareholders who treat the name as a classic clinical-stage biotech are reading last year's balance sheet.
The March licensing rewrite handed almost all remaining cost on the pivotal study to Janssen and booked a large non-cash revenue catch-up that flattered the year-end income statement. Recurring cash from the partner is still thin, mostly clinical-product sales and a modest technology-transfer recharge. The May raise added about $100 million of gross proceeds and pushed stated runway into 2029, but most of that capital is earmarked for the Nanoprimer platform rather than the lead particle. That mix is the real tension. The public market is paying for the radioenhancer. Management is using the new equity to build the next platform while the partner runs the only study that can re-rate the first one. HealthCare Royalty already owns a capped slice of the same milestone and royalty stream, so even a clean registrational win does not fall entirely to common holders.
September's full MD Anderson cohort in recurrent lung cancer showed local control at a reduced re-irradiation dose, and the first fully treated patients in the partner-sponsored Stage Three lung study showed deep responses against a historical complete-response rate that is almost nonexistent under chemoradiation plus durvalumab. Neither dataset is a registrational result. The capitalization near $1.7 billion already treats the head and neck study as more likely than not to work and treats lung as a live second shot. The question the next year actually answers is simpler than the platform rhetoric. Does the partner deliver a final analysis that supports a filing, or does the equity discover that early lung signals and a longer cash runway were never a substitute for pivotal proof?